On March 23, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO Europe Spring Investor Conference (Press release, Genprex, MAR 23, 2022, View Source [SID1234610741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: BIO Europe Spring Investor Conference

Conference Dates: March 28-31, 2022

Presentation Time: Available on-demand throughout duration of the conference

Presenter: Rodney Varner, President and Chief Executive Officer

Conference Registration: https://bit.ly/3hNGjcW

At the event, Mr. Varner will be available to participate in virtual one-on-one meetings with registered participants. A recording of this presentation will be available for replay on Genprex’s website for a period of time.